MarketPeel
Insider Trading Intelligence
Pricing
…
CH

Christopher Hite

VERA
DIRECTOR · VERA THERAPEUTICS, INC. · CIK 0001814238
FILING MIX · LIFETIME56%/44%
BUYS
14
SELLS
11
TOTAL VALUE
$38.48M
COMPANIES
3
ACTIVE SINCE
Jun 2020
HOLDINGS NOW
86,437
AVG SELL PX
$88.65
TRADE KIND
SHOWING 25 / 25
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizonsHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Christopher Hite, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+100.00%+0.98%+0.18%+0.81%+0.81%—
14d2+50.00%-6.56%+2.43%-8.99%-8.99%—
30d2+50.00%-7.27%+4.75%-12.02%-12.02%—
60d2+50.00%-8.22%+7.69%-15.91%-15.91%—
90d2+50.00%-10.58%+8.78%-19.36%-19.36%—
180d2+50.00%-14.20%+15.85%-30.05%-30.05%—
1y2+50.00%-11.35%+25.55%-36.91%-36.91%—
2y2+50.00%-19.09%+12.67%-31.76%-31.76%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
Not enough transaction history to chart holdings.
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
2026
FLOW · 14 buys / 11 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
RPRX
ROYALTY PHARMA PLC
SALEGRANT
Gift
16,800——23,200Aug 19, 2026Aug 19, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
100,000$59.97$6.00M370,401Aug 18, 2026Aug 19, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASEGRANT
Stock grant
11,002——470,401Aug 5, 2026Aug 7, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
97,446$56.50$5.51M461,953Jun 30, 2026Jul 2, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
600$57.09$34.3K40,000Jun 30, 2026Jul 2, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
29,400$56.44$1.66M40,600Jun 30, 2026Jul 2, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
2,554$57.10$145.8K459,399Jun 30, 2026Jul 2, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
117,592$54.47$6.41M559,399Jun 23, 2026Jun 25, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE10b5-1
10b5-1 plan
32,408$54.11$1.75M676,991Jun 23, 2026Jun 25, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASEGRANT
Stock grant
24,263——709,399May 6, 2026May 8, 2026 ↗View →
KLRA
KAILERA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
38,300——38,300Apr 16, 2026Apr 20, 2026 ↗View →
VERA
VERA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
24,937——24,937Mar 5, 2026Mar 9, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASEGRANT
Stock grant
26,626——685,136Feb 11, 2026Feb 13, 2026 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASEGRANT
Stock grant
6,168——658,510Nov 5, 2025Nov 7, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASEGRANT
Stock grant
3,696——652,342Aug 6, 2025Aug 8, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASEGRANT
Stock grant
1,238,789——1,238,789May 16, 2025May 20, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASEGRANT
Stock grant
48,646——648,646May 8, 2025May 9, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE
EVP & Vice Chairman
30,000——86,641Feb 14, 2025Feb 18, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASE
EVP & Vice Chairman
300,000——600,000Feb 14, 2025Feb 18, 2025 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE
EVP & Vice Chairman
30,000——541May 13, 2024May 16, 2024 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASE
EVP & Vice Chairman
300,000——370,000May 13, 2024May 16, 2024 ↗View →
RPRX
ROYALTY PHARMA PLC
SALE
EVP & Vice Chairman
31,959$469.86$15.02M30,541Mar 23, 2021Mar 25, 2021 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASE
EVP & Vice Chairman
70,000$28.00$1.96M70,000Jun 18, 2020Jun 23, 2020 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASEGRANT
Stock grant
116,100——116,100Jun 15, 2020Jun 23, 2020 ↗View →
RPRX
ROYALTY PHARMA PLC
PURCHASEGRANT
Stock grant
62,500——62,500Jun 15, 2020Jun 23, 2020 ↗View →
Other insiders · VERA
Loading peer insiders…
About this filer
CIK 0001814238
ROLE
Director
PRIMARY
VERA
COMPANIES
3
ACTIVE SINCE
Jun 2020
MARKETPEEL · /INSIDER/0001814238DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback